Published in J Clin Exp Neuropsychol on July 25, 2007
Cognitive Training for the Remediation of Functional Brain Health in HIV | NCT02571504
Challenges in addressing depression in HIV research: assessment, cultural context, and methods. AIDS Behav (2011) 1.22
Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study. J Int AIDS Soc (2010) 1.20
Anxiety symptoms and disorders among adults living with HIV and AIDS: A critical review and integrative synthesis of the empirical literature. Clin Psychol Rev (2016) 0.75
HIV-1 Vpr disrupts mitochondria axonal transport and accelerates neuronal aging. Neuropharmacology (2017) 0.75
Understanding and optimizing brain health in HIV now: protocol for a longitudinal cohort study with multiple randomized controlled trials. BMC Neurol (2016) 0.75
The Mental Health of People Living with HIV in China, 1998-2014: A Systematic Review. PLoS One (2016) 0.75
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry (2008) 9.00
Identification of separable cognitive factors in schizophrenia. Schizophr Res (2004) 5.34
Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol (2004) 5.18
Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res (2004) 5.14
Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol (2004) 4.90
Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry (2006) 4.77
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry (2004) 4.46
Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev (2007) 3.57
Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry (2007) 3.42
Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc (2004) 3.21
Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol (2004) 3.12
Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on an NIMH-sponsored workshop. Schizophr Bull (2006) 2.53
Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol (2008) 2.42
Generalized cognitive impairments, ability to perform everyday tasks, and level of independence in community living situations of older patients with psychosis. Am J Psychiatry (2002) 2.39
Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am J Psychiatry (2005) 2.34
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS (2011) 2.31
Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe (2008) 2.30
Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol (2002) 2.28
Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. Clin Neuropsychol (2004) 2.22
Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS (2006) 2.13
Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-Card Version. J Clin Exp Neuropsychol (2011) 2.06
Neuropathologic confirmation of definitional criteria for human immunodeficiency virus-associated neurocognitive disorders. J Neurovirol (2007) 2.03
Prospective memory in HIV-1 infection. J Clin Exp Neuropsychol (2006) 1.99
On-chip single-copy real-time reverse-transcription PCR in isolated picoliter droplets. Anal Chem (2008) 1.96
Testing the 8-syndrome structure of the child behavior checklist in 30 societies. J Clin Child Adolesc Psychol (2007) 1.94
Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr Bull (2008) 1.81
Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol (2011) 1.73
What do we know about neuropsychological aspects of schizophrenia? Neuropsychol Rev (2009) 1.73
Cognition assessment using the NIH Toolbox. Neurology (2013) 1.73
Incidence and nature of cognitive decline over 1 year among HIV-infected former plasma donors in China. AIDS (2010) 1.66
Correlation of in vivo neuroimaging abnormalities with postmortem human immunodeficiency virus encephalitis and dendritic loss. Arch Neurol (2004) 1.65
Action (verb) fluency: test-retest reliability, normative standards, and construct validity. J Int Neuropsychol Soc (2005) 1.65
Performance-based measurement of functional disability in schizophrenia: a cross-national study in the United States and Sweden. Am J Psychiatry (2009) 1.65
I. NIH Toolbox Cognition Battery (CB): introduction and pediatric data. Monogr Soc Res Child Dev (2013) 1.61
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol (2011) 1.57
Two-year prospective study of major depressive disorder in HIV-infected men. J Affect Disord (2007) 1.56
The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS (2005) 1.55
Validating measures of real-world outcome: the results of the VALERO expert survey and RAND panel. Schizophr Bull (2009) 1.54
Incident major depression does not affect neuropsychological functioning in HIV-infected men. J Int Neuropsychol Soc (2007) 1.54
Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS (2004) 1.54
Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings. AIDS (2004) 1.53
A six-factor model of cognition in schizophrenia and related psychotic disorders: relationships with clinical symptoms and functional capacity. Schizophr Bull (2004) 1.53
The 50 and 100-item short forms of the Paced Auditory Serial Addition Task (PASAT): demographically corrected norms and comparisons with the full PASAT in normal and clinical samples. J Clin Exp Neuropsychol (2003) 1.51
Correlations of functional capacity and neuropsychological performance in older patients with schizophrenia: evidence for specificity of relationships? Schizophr Res (2006) 1.47
Validating the measurement of real-world functional outcomes: phase I results of the VALERO study. Am J Psychiatry (2011) 1.47
The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenia patients. Biol Psychiatry (2003) 1.46
Medication and finance management among HIV-infected adults: the impact of age and cognition. J Clin Exp Neuropsychol (2010) 1.46
The generalizability of the Youth Self-Report syndrome structure in 23 societies. J Consult Clin Psychol (2007) 1.45
Assessing everyday functioning in schizophrenia: not all informants seem equally informative. Schizophr Res (2011) 1.37
Deficient strategic control of verbal encoding and retrieval in individuals with methamphetamine dependence. Neuropsychology (2005) 1.33
Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology (2013) 1.33
Depression and suicidality in HIV/AIDS in China. J Affect Disord (2006) 1.32
Epidemiological comparisons of problems and positive qualities reported by adolescents in 24 countries. J Consult Clin Psychol (2007) 1.32
HIV-associated neurocognitive disorders in sub-Saharan Africa: a pilot study in Cameroon. BMC Neurol (2010) 1.31
Construct validity of Hopkins Verbal Learning Test-Revised component process measures in an HIV-1 sample. Arch Clin Neuropsychol (2005) 1.31
Neurocognitive functioning in acute or early HIV infection. J Neurovirol (2010) 1.27
Course of neurocognitive deficits in the prodrome and first episode of schizophrenia. Neuropsychology (2010) 1.22
Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion. Arch Neurol (2003) 1.22
Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure. Drug Alcohol Depend (2004) 1.21
Depression, cognition, and self-appraisal of functional abilities in HIV: an examination of subjective appraisal versus objective performance. Clin Neuropsychol (2011) 1.21
Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence. AIDS Care (2012) 1.21
Subjective and objective quality of life in schizophrenia. Schizophr Res (2007) 1.21
Heterogeneity in functional status among older outpatients with schizophrenia: employment history, living situation, and driving. Schizophr Res (2002) 1.20
Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection. AIDS Behav (2006) 1.19
Neurocognitive impact of substance use in HIV infection. J Acquir Immune Defic Syndr (2011) 1.16
Development and Pilot Testing of a Novel Compensatory Cognitive Training Intervention for People with Psychosis. Am J Psychiatr Rehabil (2008) 1.15
Stability of cognitive performance in older patients with schizophrenia: an 8-week test-retest study. Am J Psychiatry (2005) 1.14
Mapping brain structure in attention deficit-hyperactivity disorder: a voxel-based MRI study of regional grey and white matter volume. Psychiatry Res (2007) 1.13
Neurobehavioral effects of HIV-1 infection in China and the United States: a pilot study. J Int Neuropsychol Soc (2007) 1.12
Predictors of the accuracy of self assessment of everyday functioning in people with schizophrenia. Schizophr Res (2012) 1.12
APOE epsilon4 and MBL-2 O/O genotypes are associated with neurocognitive impairment in HIV-infected plasma donors. AIDS (2010) 1.12
A battery approach for measuring neuropsychological change. Arch Clin Neuropsychol (2005) 1.11
The immunological potential of galectin-1 and -3. Autoimmun Rev (2008) 1.11
Longer term improvement in neurocognitive functioning and affective distress among methamphetamine users who achieve stable abstinence. J Clin Exp Neuropsychol (2010) 1.10
Predictive validity of demographically adjusted normative standards for the HIV Dementia Scale. J Clin Exp Neuropsychol (2007) 1.10
Abbreviated neuropsychological assessment in schizophrenia: prediction of different aspects of outcome. J Clin Exp Neuropsychol (2009) 1.10
HIV-associated neurocognitive disorder in Australia: a case of a high-functioning and optimally treated cohort and implications for international neuroHIV research. J Neurovirol (2014) 1.10
A neuropsychological investigation of multitasking in HIV infection: implications for everyday functioning. Neuropsychology (2011) 1.09
Methamphetamine use parameters do not predict neuropsychological impairment in currently abstinent dependent adults. Drug Alcohol Depend (2009) 1.08
Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis. Hepatology (2011) 1.07
Sex differences in neuropsychological performance as an effect of human immunodeficiency virus infection: a pilot study in Zambia, Africa. J Nerv Ment Dis (2012) 1.06
Computerized reaction time battery versus a traditional neuropsychological battery: detecting HIV-related impairments. J Int Neuropsychol Soc (2003) 1.06
Lifetime suicidal ideation and attempt are common among HIV+ individuals. J Affect Disord (2011) 1.06
Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. Clin Infect Dis (2013) 1.05
Compensatory cognitive training for psychosis: effects in a randomized controlled trial. J Clin Psychiatry (2012) 1.05
Neurocognitive impairment in HIV-1 clade C- versus B-infected individuals in Southern Brazil. J Neurovirol (2013) 1.05
Validity of cognitive complaints in substance-abusing patients and non-clinical controls: the Patient's Assessment of Own Functioning Inventory (PAOFI). Psychiatry Res (2009) 1.04
Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine (2012) 1.03
Neuropsychological effects of 2-week continuous positive airway pressure treatment and supplemental oxygen in patients with obstructive sleep apnea: a randomized placebo-controlled study. J Clin Sleep Med (2007) 1.03
Stress and health-related quality of life among HIV-infected persons in Hong Kong. AIDS Behav (2004) 1.02
Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation. Schizophr Res (2012) 1.01
The impact of neuropsychological functioning and depressed mood on functional complaints in HIV-1 infection and methamphetamine dependence. J Clin Exp Neuropsychol (2007) 1.01
The course of neuropsychological performance and functional capacity in older patients with schizophrenia: influences of previous history of long-term institutional stay. Biol Psychiatry (2010) 1.00
The immunobiology of colitis and cholangitis in interleukin-23p19 and interleukin-17A deleted dominant negative form of transforming growth factor beta receptor type II mice. Hepatology (2012) 0.98
An evaluation of longitudinal neurocognitive performance among middle-aged and older schizophrenia patients: use of mixed-model analyses. Schizophr Res (2006) 0.97
Cognitive-behavioral group program for Chinese heterosexual HIV-infected men in Hong Kong. Patient Educ Couns (2005) 0.97
Impairments in fine-motor coordination and speed of information processing predict declines in everyday functioning in hepatitis C infection. J Clin Exp Neuropsychol (2008) 0.96
Caspase induction by IgA antimitochondrial antibody: IgA-mediated biliary injury in primary biliary cirrhosis. Hepatology (2004) 0.95